Dr. Lekakis on Managing the Toxicity of CAR T-Cell Therapy

Video

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses managing the toxicity of CAR T-cell therapy.

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses ways of managing the toxicity of CAR T-cell therapy.

One of the biggest challenges with CAR T-cell therapy is the toxicity profile, as there are a number of unanswered questions, Lekakis says. For grade 3/4 neurotoxicity, high-dose steroids are typically given. Steroids may also be appropriate for patients with grade 2 neurotoxicity, says Lekakis. However, researchers don’t yet know the impact of corticosteroids on T cells.

One toxicity that researchers struggle with is a rare condition called cerebral edema, Lekakis notes. This is the most severe case of neurotoxicity a patient can develop. Cerebral edema occurs in 1% to 2% of patients treated with CAR T-cell therapy, but it is mostly fatal. Physicians currently manage this with corticosteroids in an attempt to induce hypocapnia, but it remains a major challenge.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.